Gainers

• Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday's pre-market session. The company's market cap stands at $1.4 million.
• OneMedNet (NASDAQ:ONMD) shares moved upwards by 12.84% to $0.8. The company's market cap stands at $40.3 million.
• NeoGenomics (NASDAQ:NEO) shares rose 11.94% to $15.0. The market value of their outstanding shares is at $1.7 billion. As per the press release, Q2 earnings came out yesterday.
• Anika Therapeutics (NASDAQ:ANIK) stock moved upwards by 10.56% to $16.75. The company's market cap stands at $201.5 million. The company's, Q2 earnings came out today.
• GE HealthCare Techs (NASDAQ:GEHC) shares moved upwards by 9.09% to $69.94. The company's market cap stands at $29.1 billion. As per the news, the Q2 earnings report came out today.
• Option Care Health (NASDAQ:OPCH) stock rose 9.03% to $24.51. The market value of their outstanding shares is at $3.5 billion. As per the news, the Q2 earnings report came out today.

Losers

• Processa Pharma (NASDAQ:PCSA) stock declined by 36.1% to $1.95 during Wednesday's pre-market session. The company's market cap stands at $8.4 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock declined by 16.67% to $0.05. The company's market cap stands at $2.2 million.
• rYojbaba (NASDAQ:RYOJ) stock decreased by 12.63% to $4.36. The company's market cap stands at $56.1 million.
• NeuroPace (NASDAQ:NPCE) shares decreased by 10.39% to $13.72. The market value of their outstanding shares is at $521.9 million.
• Radiopharm Theranostics (NASDAQ:RADX) shares declined by 10.28% to $2.97. The market value of their outstanding shares is at $25.7 million.
• Curanex Pharmaceuticals (NASDAQ:CURX) stock declined by 9.65% to $0.18. The market value of their outstanding shares is at $5.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.